Emerging research suggest this peptide, a dual stimulator targeting both GLP-1 and another hormone, could represent a significant advancement for obesity management . Early clinical tests have shown considerable reductions in visceral mass , conceivably exceeding current obesity therapies . Nevertheless , further evaluation is necessary to thorough